logo
Share SHARE
FONT-SIZE Plus   Neg

AVEO Pharma Q3 Loss Widens; To Cut Jobs - Quick Facts

AVEO Pharmaceuticals Inc. (AVEO) reported that its third-quarter net loss widened to $30.1 million, or $0.69 per share, from $23.8 million, or $0.55 per share, for the third quarter of 2011.

Total collaboration revenue for the third quarter of 2012 was approximately $1.0 million compared with $3.6 million for the third quarter of 2011. The decrease was due to revenue recognized in the third quarter of 2011 under AVEO's collaboration agreement with OSI that did not recur during the third quarter of 2012.

Analysts polled by Thomson Reuters expected the company to report a loss of $0.87 per share on revenues of $6.57 million for the quarter. Analysts' estimates typically exclude special items.

The company updated its financial guidance that it expects to end 2012 with approximately $135 million in cash, cash equivalents and marketable securities. Based on its revised operating plan, AVEO anticipates that this capital is sufficient to fund its operations through 2013.

In addition, the company plans to explore further development of ficlatuzumab and certain discovery assets through external collaborations, including with academic partnerships and cooperative groups. The company plans to focus its Human Response Platform and discovery capabilities on supporting the clinical development of tivozanib, advancing biomarker identification and development across AVEO's clinical stage programs, and developing novel, high potential programs.

The company strategic restructuring and projected cost savings are being achieved through a combination of reduced spending on early stage research programs and a reduction in force of approximately 45 positions, or 17% of AVEO's workforce, as well as elimination of 30 open positions.

This refocusing of resources and reduction of expenses is expected to provide AVEO approximately $100 million in cost savings over the next three years compared with prior projections, with approximately $37 million in 2013, and is expected to extend its cash runway through 2013.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Shares of U.S. grains trader Bunge Ltd. climbed around 17 percent on Tuesday after the Swiss mining giant Glencore Plc confirmed that its agriculture joint venture has made an informal takeover approach. Bunge, meanwhile, said its not engaged in business combination talks with Glencore or its JV Glencore Agriculture Limited. A United Airlines flight from Shanghai to New Jersey was delayed for hours as an unruly passenger refused to vacate the seat of another passenger while boarding the aircraft in Shanghai. The flight was also forced to make an unscheduled stop at San Francisco International Airport to get a replacement crew after delays caused by the passenger. Nacho cheese sauce sold at a Sacramento gas station has tested positive for the toxin that causes botulism and killed one person, according to health officials. The California Department of Public Health or CDPH said it has confirmed that the cheese sauce sold at the gas station in Sacramento County tested positive for the toxin that causes botulism.
comments powered by Disqus
Follow RTT